Aspirin intolerance and the cyclooxygenaseleukotriene pathways

Current Opinion in Pulmonary Medicine

Volumn 10, Issue 1, 2004, Pages 51-56

  Szczeklik, Andrew ^a   Sanak, Marek ^a   Nizankowska Mogilnicka, Ewa ^a   Kiełbasa, Bogumila ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antiinflammatory drugs; Aspirin induced asthma; Cyclooxygenases; Leukotrienes

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPYRONE; IBUPROFEN; ICOSANOID; IMMUNOGLOBULIN E; LEUKOTRIENE; LIPOXIN; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEPTIDOLEUKOTRIENE; PHENACETIN; PLACEBO; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID; RECEPTOR; ROFECOXIB; UNINDEXED DRUG; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

ABDOMINAL PAIN; ASPIRIN INDUCED ASTHMA; ASPIRIN INDUCED URTICARIA SYNDROME; ASTHMA; ATOPY; AUTOIMMUNITY; BIOSYNTHESIS; BRONCHOSPASM; CARDIOVASCULAR SYSTEM; CELL ACTIVATION; CELL POPULATION; CLINICAL FEATURE; DESENSITIZATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPIDEMIOLOGICAL DATA; FLUSHING; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; INFLAMMATION; LIPID METABOLISM; LIPOGENESIS; LUNG DISEASE; MAST CELL; MOLECULAR BIOLOGY; MOLECULAR CLONING; NOSE CONGESTION; NOSE POLYP; NOSE SURGERY; PREVALENCE; PROVOCATION TEST; RETROSTERNAL PAIN; REVIEW; RHINITIS; RHINOMETRY; RHINORRHEA; RHINOSINUSITIS; SHOCK; SIDE EFFECT; SINUSITIS; SKIN MANIFESTATION; SYNDROME; URTICARIA; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ASPIRIN; ASTHMA; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; ISOENZYMES; LEUKOTRIENES; LIPOXINS; MAST CELLS; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RHINITIS; SINUSITIS;

EID: 0346963363     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200401000-00009     Document Type: Review

References (75)

1. Samter M, Beers RF: Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968, 68:975-983.
2. Szczeklik A, Stevenson DD: Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003, 111:913-921. This is the most recent, comprehensive review on mechanisms operating in AIA and its clinical management.
3. Hedman J, Kaprio J, Poussa T, et al.: Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999, 28:717-722.
4. Kasper {, Sladek K, Duplaga M, et al.: Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 2003, in press.
5. Vally H, Taylor ML, Thompson PJ: The prevalence of aspirin-intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002, 57:569-574.
6. Szczeklik A, Ni1/4ankowska E, Duplaga M, et al.: Natural history of aspirin-induced asthma. Eur Respir J 2000, 16:432-436.
7. Berges-Gimeno MP, Simon RA, Stevenson DD: The natural history and clinical characteristics of aspirin exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002, 89:472-478.
8. Sampson AP: Drug-induced asthma: NSAID beta-blockers and ACE inhibitors. In Difficult Asthma. Edited by Holgate ST, HA Boushey, and Fabbri LM. Martin Dunitz; London 1999:127-138.
9. Rosado A, Vives R, Gonzalez R, et al.: Can NSAIDs intolerance disappear? A study of three cases. Allergy 2003, 58:689-690.
10. Bochenek G, Nizankowska E, Szczeklik A: The atopy trait in hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 1996, 51:16-23.
11. Kalyoncu AF, Karakaya G, Sahin AA, et al.: Occurrence of allergic conditions in asthmatic with analgesic intolerance. Allergy 1999, 54:428-435.
12. Pastorello EA, Zara C, Riario-Sforza GG, et al.: Atopy and intolerance of antimicrobial drugs increase the risk of reactions to acetaminophen and Nimesulide in patients allergic to nonsteroidal anti-inflammatory drugs. Allergy 1998, 53:880-884.
13. Berges-Gimeno M, Simon RA, Stevenson DD: Treatment with aspirin desensitization in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol 2003, 111:180-186. This article reports clinical results by one of the most experienced groups in aspirin desensitization.
14. Kowalski ML, Grzegorczyk J, Pawliczak R, et al.: Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. Allergy 2002, 57:493-500.
15. Setkowicz M, Zembowicz A, Mastalerz L, et al.: NSAIDs sensitivity in chronic idiopathic urticaria: selective involvement of cyclooxygenase-1 and overproduction of cysteinyl-leukotrienes. J Allergy Clin Immunol 2003, 111:S272.
16. Higashi N, Taniguchi M, Mita H, et al.: Aspirin-induced urticaria and angio-edema, but not bronchoconstriction, associated with cysteinyl leukotriene overproduction in 2 patients with asthma. J Allergy Clin Immunol 2002, 110:666-667.
17. Szczeklik A, Nizankowska E, Mastalerz L, et al.: Myocardial ischemia possibly mediated by cysteinyl leukotrienes. J Allergy Clin Immunol 2002, 109:572-573.
18. Mattucci L, Rossi O, Cecchi L, et al.: Coronary vasospasm during an acute allergic reaction. Allergy 2002, 57:865-866.
19. Martin XD, Duvoisin B: Ocular complications of the Fernand-Widal triad and its therapy. Ophthalmologica 2003, 217:160-163.
20. Szczeklik A, Nizankowska E, Serafin A, et al.: Autoimmune phenomena in bronchial asthma with special reference to aspirin intolerance. Am J Respir Crit Care Med 1995, 152:1753-1756.
21. Asero R, Tadeschi A, Lorini M: Autoreactivity is highly prevalent in patients with multiple intolerance to NSAIDs. Ann Allergy Asthma Immunol 2002, 88:175-179.
22. Melillo G, Balzano G, Bianco S, et al.: Report of the INTERASMA Working Group on standardization of inhalation provocation tests in aspirin-induced asthma. Allergy 2001, 56:899-911.
23. Ni1/4ankowska E, Bestynska-Krypel A, Cmiel A, et al.: Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000, 15:863-869.
24. Milewski M, Mastalerz L, Nizankowska E, et al.: Nasal provocation test for diagnosis of aspirin-induced asthma. J Allergy Clin Immunol 1998, 101:581-586.
25. Alonso-Llamazares A, Martinez-Cocera C, Dominguez-Ortega J, et al.: Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Allergy 2002, 57:632-635.
26. Casadevall J, Ventura P, Mullol J, et al.: Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000, 55:921-924.
27. Bochenek G, Nizankowska E, Szczeklik A: Testing for aspirin hypersensitivity. Allergy 2002, 57:562-565.
28. Antczak A, Montuschi P, Kharitonow S, et al.: Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002, 166:301-306. This is an interesting, new approach to the assessment of eicosanoid concentrations in exhaled air condensates. Enzyme-linked immunosorbent assay was used by the authors for eicosanoid concentration determination. Increased sensitivity might be expected with future use of radioimmunoassay or gas chromatography/mass spectrometry.
29. Nasser SMS, Lee TH: Leukotrienes in aspirin-sensitive asthma. In Eicosanoids, Aspirin and Asthma. Edited by Szczeklik A, Gryglewski R, Vane J. New York: Marcel Dekker; 1998:317-337.
30. Cowburn AS, Sladek K, Soja J, et al.: Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998, 101:834-846.
31. Piliponsky AM, Gleich GJ, Bar I, et al.: Effects of eosinophils on mast cells: a new pathway of perpetuation of allergic inflammation. Mol Immunol 2001, 39:1369-1372.
32. Mita H, Endoh S, Kudoh M, et al.: Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy 2001, 56:1061-1067.
33. 2 and tryptase to blood. This might contribute to the severe clinical course of the syndrome.
34. Szczeklik A, Gryglewski R, Czerniawska-Mysik G: Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ 1975, 11:67-69.
35. 2 production under proinflammatory conditions in asthmatic airways. This could weaken local defensive mechanisms and promote Cys-LT production.
36. Chandrasekharan NV, Dai H, Roos KLT, et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002, 99:13926-13931. This paper describes cloning of a new COX isoenzyme (COX-3) and its pharmacologic properties. This landmark paper points to the growing family of COXs.
37. Chavis C, Vachier J, Godard P, et al.: Lipoxins and other arachidonate-derived mediators in bronchial asthma. Thorax 2000, 55(suppl 2):538-541.
38. Levy BD, De Sanctis GT, Devchand PR, et al.: Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med 2002, 8:1018-1023. This is an experimental, conclusive demonstration of multipotent antiinflammatory effects of lipoxins.
39. Sanak M, Levy BD, Clish CB, et al.: Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000, 16:44-49.
40. Szczeklik A, Sanak M: The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors. Clin Exp Allergy 2002, 32:339-342.
41. Kowalski ML, Pawliczak R, Wozniak J, et al.: Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000, 161:391-398.
42. Weisner R, Suzuki H, Walther M, et al.: Suicidal inactivation of the rabbit 15-lipoxygenase by 15S-HETE is paralleled by covalent modification of active site peptides. Free Rad Biol Med 2003, 34:304-315.
43. Yoshida S, Ishizaki Y, Onuma K, et al.: Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma. J Allergy Clin Immunol 2000, 106:1201-1202.
44. Szczeklik A, Nizankowska E, Bochenek G, et al.: Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001, 31:219-225.
45. Stevenson DD, Simon RA: Lack of cross-reactivity between rofecoxib and aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001, 108:47-51.
46. Woessner KM, Simon RA, Stevenson DD: The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 2002, 46:2201-2206.
47. Inoue K, Takano H, Kawahito Y, et al.: Cyclooxygenase-2 inhibitors in aspirin-induced asthma. Chest 2003, 123:1317-1318.
48. Gyllfors P, Bochenek G, Overholt J, et al.: Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003, 111:1116-1121.
49. Sousa AR, Parkih A, Scadding G, et al.: Leukotriene-receptor expression on nasal mucosa inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002, 347:1493-1499.
50. Arm J, Austen KF: Leukotriene receptors and aspirin sensitivity. N Engl J Med 2002, 347:1524-1526.
51. Nucera E, Schiavino D, Milani A, et al.: Effects of lysine- acetylsalicylate (LAS) treatment in nasal polyposis: two controlled long term prospective follow up studies. Thorax 2000, 55:S75-S78.
52. Schmitz-Schumann M, Menz G, Kohl C, et al.: Adaptive desaktivierung bei analgetika-asthma syndrom: methodik und phanomene der toleranzinduktion. Prax Klin Pneumol 1985, 39:868-869.
53. Pavord ID, Ward R, Woltmann G, et al.: Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med 1999, 160:1905-1909.
54. Zaitsu M, Hamasaki Y, Tsuji K, et al.: Dexamethasone accelerates catabolism of leukotriene C4 in bronchial epithelial cells. Eur Respir J 2003, 22:35-42. This in vitro study demonstrates a novel interaction between corticosteroids and Cys-LT metabolism.
55. Dahlen B, Nizankowska E, Szczeklik A, et al.: Benefits from adding the 5-lipooxygenase inhibitor Zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998, 157:1187-1194.
56. Dahlen SE, Malmstrom K, Nizankowska E, et al.: Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist. A randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:9-14.
57. Yoshida S, Sakamoto H, Ishizaki Y, et al.: Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma. Clin Exp Allergy 2000, 30:64-70.
58. Stevenson DD, Simon RA, Mathison DA, et al.: Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000, 85:477-482.
59. Enrique E, Garcia-Ortega P, Gaig P, et al.: Failure of montelukast to prevent anaphylaxis to diclofenac. Allergy 1999, 54:529-530.
60. Berges-Gimeno MP, Simon RA, Stevenson DD: The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 2002, 32:1491-1496.
61. Szczeklik A, Mastalerz L, Niżankowska E, et al.: Montelukast for persistent asthma. Lancet 2001, 358:1456-1457.
62. Mastalerz L, Nizankowska E, Sanak M, et al.: Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002, 32:1360-1365.
63. Mastalerz L, Gawlewicz-Mroczka A, Niżankowska E, et al.: Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin Exp Allergy 2002, 32:1360-1365.
64. Ragab S, Parikh A, Darby YC, et al.: An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 2001, 31:1385-1391.
65. 4 synthase gene confers better response to Cys-LT antagonists in asthma. This is important information in the rapidly developing field of pharmacogenetics.
66. Sampson AP, Siddiqui S, Buchanan D, et al.: Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000, 55:S28-S31.
67. Szczeklik A, Mastalerz L, Nizankowska E, et al.: Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med 1996, 153:567-571.
68. Shoji T, Yoshida S, Sakamoto H, et al.: Anti-inflammatory effect of Roxitromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999, 29:950-956.
69. Yoshida S, Sakamoto H, Yamawaki Y, et al.: Effect of acyclovir on broncho-constriction and urinary leukotriene E4 excretion in aspirin-induced asthma. J Allergy Clin Immunol 1998, 102:909-914.
70. Amayasu H, Nakabayashi M, Akahori K, et al.: Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerant asthma. Ann Allergy Asthma Immunol 2001, 87:146-150.
71. Picado C: Aspirin intolerance and nasal polyposis. Curr Allergy Asthma Rep 2002, 2:488-493.
72. Scadding GK: Comparison of medical and surgical treatment of nasal polyposis. Curr Allergy Asthma Rep 2002, 2:494-499.
73. Mastalerz L, Milewski M, Duplaga M, et al.: Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. Allergy 1997, 52:895-900.
74. Holgate ST, Peters-Golden M, Panettieri RA, et al.: Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003, 111:S18-S36.
75. Tattersfield AE, Knox AJ, Britton JR, et al.: Asthma. Lancet 2002, 360:1313-1322. This is an excellent, succinct review on the pathogenesis and management of asthma. It contains practical information concerning AIA.